Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ABEO
ABEONA THERAPEUTICS INC.
NASDAQ
$6.00
▲ UP 1.18% (0.07)

KEY STATISTICS

Market Cap$341.97 M
52w High$7.65
52w Low$4.00
Dividend Yield8.55%
FrequencySpecial
P/E-5.50
Volume866.50K
Shares Out.57.00M

COMPANY

LEADERSHIP

Vishwas Seshadri
CHIEF EXECUTIVE
Vishwas Seshadri

COMPENSATION 2026

Salary$662,000
Stock Awards$2,472,698
Incentive Plan Pay$309,485
All Other Comp.$14,000
Total$3,991,516

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 19, 1980
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
226

PRICE TARGET

Target High$21.00
Target Low$15.00
Target Median$17.00
Target Consensus$17.67

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.$15.75M
NOV
11
WED

SPLIT RECORD

DATETYPERATIO
2022-07-05Reverse1:25
2014-10-24Reverse1:50
2006-06-05Reverse1:5
1998-06-18Reverse1:20
1998-06-05Reverse1:1
1992-04-16Reverse1:2

PRICE

$6.00 ▲ UP 1.18% (+$0.07)
OVERLAYS
$5.85$5.90$5.95$6.009:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM6.00

About Abeona Therapeutics Inc.

https://www.abeonatherapeutics.com ↗

Abeona Therapeutics Inc. is a clinical-stage biopharma developing gene and cell therapies for rare genetic diseases, including EB-101 for epidermolysis bullosa and AAV-based treatments for Sanfilippo syndrome, CLN3 disease, cystic fibrosis, and ey...

INDUSTRY

Biotechnology

A PRODUCT ABEONA THERAPEUTICS INC. IS KNOWN FOR

ZEVASKYN™ (prademagene zamikeracel)
ZEVASKYN™ (prademagene zamikeracel)

ZEVASKYN™ is the FDA-approved, single-application autologous gene therapy for RDEB, using genetically corrected patient skin cells to promote healing and skin adhesion in severe cases.

COMPETITORS

COMPETITOR
BBIO COMPARE
KRYS COMPARE

Revenue by Products

IconPRODUCTQ3-2018Q4-2018Q1-2026Q2-2026
Product— — $8.72M $11.38M ▲
Grant$1.69M $369K ▼— —
Royalty$22K $113K ▲— —

ETFS HOLDING THIS STOCK

ETFS HOLDING
61
LISTED HERE
15
RANKED BY POSITION SIZE
VTI
0.00% · 1.5M
IWM
0.01% · 1.2M
SURI
1.89% · 276.3K
R2US.L
0.01% · 114.6K
EES
0.08% · 94.5K
AVSC
0.01% · 64.3K
GSSC
0.03% · 63.3K
HAPS
0.17% · 50.0K
XRSU.L
0.01% · 42.8K
FESM
0.00% · 35.9K
RSSL
0.01% · 20.7K
DFAS
0.00% · 16.7K
URTY
0.00% · 1.7K
RESM
0.01% · 99
RTYS.L
0.01% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
1.35%
HOLDERS
12
TOP 12 OF 12 · RANKED BY POSITION SIZE
Qs Investors, LLC
325.0K sh · $507K
Blackrock Institutional Trust Company, N.A.
202.6K sh · $982K
Teachers Advisors, LLC
98.2K sh · $723K
Tiaa Cref Investment Management LLC
58.9K sh · $433K
Blackrock Fund Advisors
41.9K sh · $203K
Alambic Investment Management, L.P.
23.1K sh · $24K
B. Riley Wealth Management, Inc.
12.9K sh · $3K
Fortaleza Asset Management Inc/
6.5K sh · $104K
Blackrock Investment Management, LLC
2.6K sh · $13K
Magee Thomson Investment Partners LLC
127 sh · $1K
Ladenburg Thalmann Financial Services Inc.
1 sh · $0
Shine Investment Advisory Services Inc
1 sh · $0

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
DIRECTOR
Alvino Mark
Sale · 15.0K shares
2026-09-01
★
OFFICER: CHIEF FINANCIAL OFFICER
Vazzano Joseph Walter
Sale · 1.5K shares
2026-07-21
★
OFFICER: SVP, CHIEF LEGAL OFFICER
O'Malley Brendan M.
Sale · 12.1K shares
2026-07-09
★
OFFICER: CHIEF COMMERCIAL OFFICER
Vasanthavada Madhav
Sale · 12.6K shares
2026-07-09

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 1
BUY 1
2 GRADES IN THE LAST 12 MONTHS
Oppenheimer OUTPERFORM HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
ASMB$36.60COMPARE
PBYI$9.55COMPARE
ARCT$15.82COMPARE
SGMT$10.94COMPARE
FHTX$4.92COMPARE
ELDN$3.02COMPARE
VYGR$3.51COMPARE
TNYA$0.68COMPARE